共 142 条
[1]
Janssen PA(1988)Pharmacology of risperidone (R64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244 685-93
[2]
Niemegeers CJ(1997)The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 58 538-46
[3]
Awouters F(1989)Therapeutic effect and safety of increasing doses of risperidone (R64766) in psychotic patients. Psychopharmacology 99 445-9
[4]
Schellekens KH(2002)Pharmacokinetics and safety assessments of Galantamine and Risperidone after the two drugs are administered alone and together. J Clin Pharmacol 42 1341-51
[5]
Megens AA(1995)A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5–HT2 and dopamine D2 receptors. Int Clin Psycho-pharmacol 10 19-30
[6]
Meert TF(1993)Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 21 1134-41
[7]
Marder SR(1992)A predictive model for substrates of cytochrome P450-debrisoquine (2D6). Chem Res Toxicol 5 211-9
[8]
Davis DM(1993)The regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacol 15 371-9
[9]
Chouinard D(1999)Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 359 147-51
[10]
Mesotten F(2001)Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos 29 1263-8